The archive · Hardware & Devices · Strategic decision · 2025–2026
Galatek's $30M Series A bet: one AI automation stack for smart labs and chip fabs
Singapore's Galatek bets labs and chip fabs run on the same precision stack; ~$30M raised in its founding year to scale lab and chip-fab automation.
Galatek
What the business is
A Singapore deep-tech company selling AI-driven automation: smart-lab robotics and software for life sciences, plus metrology, inspection and wafer-dicing equipment for advanced semiconductor packaging.
Starting capital：~$30M Series A (Dec 2025); investors not disclosed.
How it started
Galatek was founded in 2025 in Singapore by David Tian to build AI-driven automation for life sciences and advanced semiconductor manufacturing. Its thesis: both industries run on precision, reproducibility and trustworthy data, so one stack can serve both. It built Abio, a cloud-agnostic platform unifying ELN, LIMS and SDMS with robotics, and InteVega, an AI vision engine reused from cell imaging to wafer inspection, and co-created next-generation smart labs with the National University of Singapore before raising outside capital.
What happened
In life sciences, Galatek focused on smart-lab applications including diagnostics, NGS sequencing, 3D cell and organoid culture, drug development and synthetic biology, with strategic partnerships with top-tier global pharmaceutical firms and research institutions. In semiconductors, it moved into advanced packaging with fully automated overlay measurement, deep-learning automatic optical inspection and precision wafer dicing, collaborating with several leading global semiconductor manufacturers.
How it ended up
Still live and scaling: in December 2025 Galatek announced approximately $30M in Series A funding to accelerate product development, strengthen its global supply chain and deepen local teams across Europe, North America and Southeast Asia. Its 'Global Supply Chain + Localized Service' model combines Asian manufacturing with company-owned delivery centers in Malaysia and the US; the company cites more than 34 million automated sample-processing runs.
Background
Galatek's bet is unusual on paper: one company serving life-science laboratories and advanced semiconductor manufacturing, two industries that rarely share a supplier. Its argument is that both run on the same discipline — precision, reproducibility and data you can trust — so the same vision AI, motion control and software can earn its keep twice.
Founded in Singapore in 2025 and led by CEO David Tian, Galatek built Abio, a cloud-agnostic software platform that unifies electronic lab notebooks, LIMS and SDMS with lab automation, and InteVega, an AI vision engine that analyzes both cell images and silicon defects. Before closing its first funding round, it co-created next-generation smart labs with the National University of Singapore.
In life sciences the company targets diagnostics, NGS sequencing, 3D cell and organoid culture, drug development and synthetic biology, with partnerships with top-tier pharma firms and research institutions; in semiconductors it sells automated overlay measurement, deep-learning optical inspection and precision wafer dicing to advanced-packaging customers.
In December 2025 — within a year of founding — Galatek announced approximately $30M in Series A funding (investors undisclosed) to accelerate product development, strengthen its global supply chain and deepen local teams in Europe, North America and Southeast Asia. Its 'Global Supply Chain + Localized Service' model pairs Asian manufacturing with company-owned delivery centers in Malaysia and the US, and the company cites more than 34 million automated sample-processing runs.
What has to be true
- Tian positioned Galatek at a structural moment: AI and automation are transforming both life sciences and advanced packaging, where precision defines the next generation of innovation.
- Rather than competing on hardware alone, Galatek built an integrated stack — Abio software plus InteVega vision — that can be reused across labs and fabs.
- It proved product before raise: co-creating smart labs with NUS and working with pharma and semiconductor partners before closing the Series A.
- The 'Global Supply Chain + Localized Service' model made installation and support, not just equipment, part of the pitch.
What can be applied
Find the shared discipline between two precision industries (vision, motion, data), build one stack for both, and make installation-and-service the moat rather than hardware alone.
Aftermath
As of 19 December 2025, Galatek is live and scaling: approximately $30M in Series A funding will accelerate smart-lab and advanced-packaging products, supply chain and local teams in Europe, North America and Southeast Asia. It operates a 'Global Supply Chain + Localized Service' model with delivery centers in Malaysia and the US, cites 34M+ automated sample runs and co-develops smart labs with NUS. Series A investors and valuation were not disclosed; no later funding announced.
Sources
- Singapore's Galatek raises $30M Series A funding to accelerate AI-powered automation in life sciences, semiconductor manufacturing
- SG-based Startup Galatek Raises $30M Series A to Accelerate AI-powered Automation in Life Sciences and Semiconductor Manufacturing
- Galatek — AI Automation for Life Sciences & Semiconductors
spotted an error? The archive wants to know.
Your turn
You just read one. Describe what you are building, and see who is betting on the same thing.
Free account · 3 free questions · no card